RPS6KB2 and cancer: While hnRNPA1 is not druggable per se, our data showing that S6K2 activity mediates chemoresistance in lung cancer and promotes translation of molecules linked to tumorigenesis ((4,11) and present results) suggests that this kinase may be a promising novel therapeutic target for cancer.